Novo Nordisk A/S - Share repurchase programme

January 02, 2013 08:57 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

Attachments

Company Announcement No 01 2013

Company Announcement No 01 2013...

Recommended Reading

April 20, 2026 08:32 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Read More
April 20, 2026 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
Read More